Glucagon-Like Peptide-1 Receptor Agonists in Chronic Migraine: A Convergent Disease-Modification Hypothesis
Abstract
Chronic migraine is increasingly understood as a network-level disorder in which trigeminovascular nociception is sustained by metabolic, inflammatory, and macro-network dysfunction rather than by an isolated headache mechanism. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, engage receptors expressed in choroid plexus, cortex, hippocampus, thalamus, and hypothalamus. Evidence converges on four mechanistic intersections between GLP-1 signalling and the chronic-migraine cascade: restoration of cerebral insulin signalling and cortical energy supply; modulation of cerebrospinal-fluid secretion and intracranial pressure with downstream relevance for glymphatic dynamics (most clearly validated in idiopathic intracranial hypertension, with explicit caveats for normotensive migraine); suppression of microglial activation in pain-relevant circuits (established preclinically, with one pilot human imaging study); and direct trigeminal-nociceptor effects via TRPV1 inhibition demonstrated for exendin-derived peptides. A 2026 real-world cohort of approximately 11,000 chronic-migraine adults provides a preliminary clinical signal. We propose, and operationalise as falsifiable, the hypothesis that GLP-1RAs are disease-modifying rather than purely symptomatic in chronic migraine, and we describe a placebo-controlled trial with parallel multiple mediation analysis on weight change AND HOMA-IR/TyG delta that can refute the claim…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.